Overview

* 4D Molecular Therapeutics ( FDMT ) Q2 net loss widens to $54.7 mln from $35.0 mln

* R&D expenses rise due to Phase 3 trial initiation for 4D-150 in wet AMD

* Co streamlines organization, reducing workforce by 25% to extend cash runway

Outlook

* 4DMT expects 4FRONT-1 data in H1 2027, accelerated from H2 2027

* Company initiated 4FRONT-2 trial ahead of schedule

* 4DMT expects cash to fund operations into 2028

* Company aligns with FDA and EMA for Phase 3 trial approval

Result Drivers

* ACCELERATED TRIALS - Rapid enrollment in 4FRONT-1 trial for 4D-150 in wet AMD allows for accelerated data readout to H1 2027

* STREAMLINED OPERATIONS - Workforce reduction by 25% to focus on late-stage execution and extend cash runway into 2028

* POSITIVE TRIAL RESULTS - 60-week data from SPECTRA trial in DME shows favorable tolerability and sustained treatment benefits

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 $15,000

Revenue

Q2 Net -$54.66

Income mln

Q2 Basic -$0.98

EPS

Q2 $59.47

Operatin mln

g

Expenses

Q2 -$59.46

Operatin mln

g Income

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", 2 "hold" and 1 "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy"

* Wall Street's median 12-month price target for 4D Molecular Therapeutics Inc ( FDMT ) is $30.00, about 81.2% above its August 8 closing price of $5.63

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)